GlassScriptPhysician profile
Virginia Slaughter
NPI 1336625078
$1,212.70
in general payments reported to CMS, 2019-2025
17 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $445 · 2023: $224 · 2024: $16.03 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $679.85 | 2021-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $124.41 | 2022-2024 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $60.25 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abiomed | $40.61 | 2025 | |
| Axsome Therapeutics, INC. | $32.99 | 2022-2023 | Auvelity |
| Madrigal Pharmaceuticals | $31.92 | 2025 | Rezdiffra |
| Alkermes, INC. | $29.72 | 2022-2023 | Aristada, Lybalvi |
| Pfizer INC. | $28.17 | 2023 | |
| Abbvie INC. | $28.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.33 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $22.04 | 2023 | Ingrezza |
| Regeneron Healthcare Solutions, INC. | $19.81 | 2023 | Praluent, Evkeeza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.23 | 2023 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $16.57 | 2023 | Austedo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $14.95 | 2022 | |
| Lilly USA, LLC | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Slaughter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.